ANAB peer analysis
AnaptysBio (ANAB) against its competitors: price, today's move, 1-year return and market value side by side.
ANAB and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ACRS Aclaris Therapeutics | $3.88 | -2.27% | 55.82% | $615.29M |
| ANNX Annexon | $3.97 | -1.98% | 35.49% | – |
| ARTV Artiva Biotherapeutics | $4.19 | -0.95% | 6.35% | – |
| CNTB Connect Biopharma | $0.80 | -3.97% | -48.25% | – |
| DNTH Dianthus Therapeutics | $82.52 | 0.17% | 144.58% | – |
| IMVT Immunovant | $28.91 | -0.89% | 16.48% | $6.03B |
| MLTX MoonLake | $11.40 | -3.23% | 16.21% | – |
| ODTX Odyssey Therapeutics | $19.54 | -1.46% | – | – |
| QTTB Q32 Bio | $8.91 | 0.45% | 222.83% | – |
| XNCR Xencor | $29.75 | -0.23% | 110.54% | $2.22B |
| ANAB AnaptysBio | $47.52 | -1.57% | 30.30% | $1.44B |
- ANAB's peers: ACRS (Aclaris Therapeutics), ANNX (Annexon), ARTV (Artiva Biotherapeutics), CNTB (Connect Biopharma), DNTH (Dianthus Therapeutics), IMVT (Immunovant), MLTX (MoonLake), ODTX (Odyssey Therapeutics).
Updated 2026-11-02 17:56 UTC